Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT05158023 is registered in ClinicalTrials.gov with ASLAN Pharmaceuticals as lead sponsor.

NCT NCT05158023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05158023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
ASLAN Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
March 16, 2022
Completion date
September 5, 2023
Enrollment
302 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis